TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07683000: Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

Sponsor: Gilead Sciences · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 590 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$13,359,360

Rescue Site Savings

+$8,808,828

Unlock Full NCT07683000 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07683000 Rescue Dossier →